Kevin Knightly - IQVIA Holdings President - Information and Technology Solutions
| IQV Stock | USD 197.60 3.22 1.66% |
President
Mr. Kevin C. Knightly is President Information and Technology Solutions of the Company since October 2016. Previously Mr. Knightly served as Senior Vice President, Information Offerings at IMS Health from April 2015 to October 2016. From January 2011 to March 2015, Mr. Knightly served as Senior Vice President, Supplier Management at IMS Health. Prior to that, Mr. Knightly served in a number of senior financial, operations, marketing and general management roles for IMS Health, including as Senior Vice President, Pharma Business Management from 2007 until 2010 since 2016.
| Age | 63 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 2400 Ellis Road, Durham, NC, United States, 27703 |
| Phone | 919 998 2000 |
| Web | https://www.iqvia.com |
IQVIA Holdings Management Efficiency
The company has Return on Asset of 0.0511 % which means that on every $100 spent on assets, it made $0.0511 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.22 %, implying that it generated $0.22 on every 100 dollars invested. IQVIA Holdings' management efficiency ratios could be used to measure how well IQVIA Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IQVIA Holdings' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to climb to 0.06 in 2024, whereas Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, IQVIA Holdings' Debt To Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 22.85 in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.7 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Peter Wilkinson | Laboratory of | 53 | |
| Patrick Finn | Twist Bioscience Corp | 52 | |
| Sandra Vaart | Laboratory of | 64 | |
| Lance Berberian | Laboratory of | 61 | |
| Amol Chaubal | Waters | 47 | |
| Sherry Buck | Waters | 55 | |
| Glenn Eisenberg | Laboratory of | 63 | |
| Michael Harrington | Waters | 59 | |
| Michael Lane | IDEXX Laboratories | 55 | |
| Simon Holmes | ICON PLC | 57 | |
| Susan Burwig | Medpace Holdings | 61 | |
| Brian Caveney | Laboratory of | 47 | |
| Michael Knell | Charles River Laboratories | 47 | |
| Ian King | Waters | 63 | |
| Robert Carson | Waters | 46 | |
| Jonathan Sheldon | Qiagen NV | 52 | |
| John Lynch | Waters | N/A | |
| Elizabeth Rae | Waters | 60 | |
| Birgit Girshick | Charles River Laboratories | 54 | |
| Diarmaid Cunningham | ICON PLC | 49 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0511 |
IQVIA Holdings Leadership Team
Elected by the shareholders, the IQVIA Holdings' board of directors comprises two types of representatives: IQVIA Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IQVIA. The board's role is to monitor IQVIA Holdings' management team and ensure that shareholders' interests are well served. IQVIA Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IQVIA Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ari Bousbib, Chairman of the Board, President, Chief Executive Officer | ||
| Nicholas Childs, Senior Treasury | ||
| John Danhakl, Independent Director | ||
| Trudy Stein, Chief VP | ||
| Andrea Spannheimer, Global Research | ||
| Richard III, President Solutions | ||
| Walter Staub, President - Research and Development Solutions | ||
| Michael McDonnell, Chief Financial Officer, Executive Vice President | ||
| Andrew Markwick, VP Relations | ||
| Carol Burt, Independent Director | ||
| Jon Resnick, President Canada | ||
| John Leonard, Lead Independent Director | ||
| Keriann Cherofsky, Corporate VP | ||
| Gregg Dearhammer, Safety Sciences | ||
| Cynthia Verst, President Innovation | ||
| Jeffrey MD, Global VP | ||
| James Fasano, Independent Director | ||
| Ronald Bruehlman, Interim Chief Financial Officer, Executive Vice President | ||
| Jeffrey Spaeder, Global VP | ||
| Eric JD, General VP | ||
| John Connaughton, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Nilton Paletta, President America | ||
| Todd Sisitsky, Independent Director | ||
| Eric Sherbet, Executive Vice President General Counsel, Secretary | ||
| Costa Panagos, President - Research & Development Solutions | ||
| Lucas Glass, Global Excellence | ||
| Rob Kotchie, President Solutions | ||
| Wendy Stewart, President Operations | ||
| Kerri Joseph, SVP Treasury | ||
| Jim Berkshire, Executive Operations | ||
| Alistair Grenfell, Middle Europe | ||
| Karl Guenault, Senior Officer | ||
| Ronald Rittenmeyer, Independent Director | ||
| Brian Mi, President Pacific | ||
| Kevin Knightly, President - Information and Technology Solutions |
IQVIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IQVIA Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0511 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 47.27 B | ||||
| Shares Outstanding | 181.5 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 94.25 % | ||||
| Number Of Shares Shorted | 2.62 M | ||||
| Price To Earning | 103.68 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IQVIA Stock Analysis
When running IQVIA Holdings' price analysis, check to measure IQVIA Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IQVIA Holdings is operating at the current time. Most of IQVIA Holdings' value examination focuses on studying past and present price action to predict the probability of IQVIA Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IQVIA Holdings' price. Additionally, you may evaluate how the addition of IQVIA Holdings to your portfolios can decrease your overall portfolio volatility.